Early clinical development of anti-tuberculosis drugs: Science, statistics and sterilizing activity

Tuberculosis

Volumn 90, Issue 3, 2010, Pages 171-176

  Davies, Geraint R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Clinical Trials; Methodology; Pharmacology; Tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL COUNT; BACTERIUM CULTURE; CLINICAL TRIAL; CULTURE TECHNIQUE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG QUALITY; DRUG RESEARCH; HUMAN; LIQUID CULTURE; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; REVIEW; SPUTUM ANALYSIS; STATISTICAL ANALYSIS; TREATMENT RESPONSE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLONY COUNT, MICROBIAL; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; STERILIZATION; TUBERCULOSIS;

EID: 77952541717     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2010.03.007     Document Type: Review

References (35)

1. Ginsberg A.M., and Spigelman M. Challenges in tuberculosis drug research and development. Nature Medicine 13 (2007) 290-294
2. Mitchison D. Role of individual drugs in the chemotherapy of tuberculosis. International Journal of Tuberculosis and Lung Disease 4 (2000) 262-267
3. Mitchison D.A., and Davies G.R. Assessment of the efficacy of new anti-tuberculosis drugs. Open Infectious Diseases Journal 2 (2008) 59-76
4. MRC. Streptomycin treatment of pulmonary tuberculosis. British Medical Journal 2 (1948) 769-782
5. MRC. Streptomycin treatment of tuberculous meningitis. Lancet 1 (1948) 582-596
6. Mitchison D. The Garrod Lecture. Understanding the chemotherapy of tuberculosis-current problems. Journal of Antimicrobial Chemotherapy 29 (1992) 477-493
7. Hobby G.L., Auerbach O., Lenert T.F., Small M.J., and Comer J.V. The late emergence of M. tuberculosis in liquid cultures of pulmonary lesions resected from humans. American Review of Tuberculosis 70 2 (1954) 191-218
8. Council E.A.M.R. Controlled clinical trial of five short-course (4 month) chemotherapy regimens in pulmonary tuberculosis. Second report of the fourth study. American Review of Respiratory Disease 123 (1981) 165-170
9. Mitchison D. Basic mechanisms of chemotherapy. Chest 76 6 Suppl. (1979) 771-781
10. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine 8 4 (1989) 431-440
11. Buyse M., Molenberghs G., Burzykowski T., Renard D., and Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1 1 (2000) 49-67
12. Molenberghs G., Buyse M., and Bursykowski T. A meta-analytic framework for continuous outcomes. The evaluation of surrogate endpoints (2005), Springer, New York
13. Baker S.G., and Kramer B.S. A perfect correlate does not a surrogate make. BMC Med Res Methodol 3 (2003) 16
14. Sheiner L.B. Learning versus confirming in clinical drug development. Clinical Pharmacology and Therapeutics 61 3 (1997) 275-291
15. Wallis R.S., Doherty T.M., Onyebujoh P., Vahedi M., Laang H., Olesen O., et al. Biomarkers for tuberculosis disease activity, cure, and relapse. The Lancet Infectious Diseases 9 3 (2009) 162-172
16. van Niekerk C., and Ginsberg A. Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes?. International Journal of Tuberculosis and Lung Disease 13 11 (2009) 1367-1372
17. Mitchison D. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at two months. American Review of Respiratory Diseases 147 (1993) 1062-1063
18. Phillips P, Fielding K. The evaluation of culture conversion during treatment for tuberculosis as a surrogate marker for relapse. Cape Town: International Union against Tuberculosis and Lung Disease Conference; 2007.
19. Phillips PPJK, Fielding K. Surrogate markers for poor outcome to treatment for tuberculosis: results from extensive multi-trial analysis. Paris: International Union against Tuberculosis and Lung Disease Conference; 2008.
20. Jindani A., Aber V., Edwards E., and Mitchison D. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. American Review of Respiratory Diseases 121 (1980) 939-949
21. Donald P., Sirgel F., Venter A., Parkin D., Seifart H., Wal B.V.D., et al. Early bactericidal activity of antituberculosis agents. Expert Reviews in Anti-Infective Therapy 1 1 (2003) 141-155
22. Sirgel F., Donald P., Odhiambo J., Githui W., Umapathy K., Paramasivan C., et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. Journal of Antimicrobial Chemotherapy 45 (2000) 859-870
23. Sirgel F., Venter A., and Mitchison D. Sources of variation in studies of the early bactericidal activity of antituberculosis drugs. Journal of Antimicrobial Chemotherapy 47 (2001) 177-182
24. Jindani A., Dore C., and Mitchison D. The bactericidal and sterilising activities of antituberculosis drugs during the first fourteen days. American Journal of Respiratory and Critical Care Medicine (2003)
25. Diacon A., Rustomjee R., McNeely D., Kerstens R., Marez T.D., and Andries K. Early bactericidal activity, tolerability, and pharmacokinetics of the investigational diarylquinoline TMC207. International Journal of Tuberculosis and Lung Disease 10 Suppl. 1 (2006) S165
26. Rustomjee R., Lienhardt C., Kanyok T., Davies G.R., Levin J., Mthiyane T., et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 12 2 (2008) 128-138
27. Davies G., Khoo S., and Aarons L. Use of nonlinear mixed effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrobial Agents and Chemotherapy 50 9 (2006) 3154-3156
28. Burman W., Goldberg S., Johnson J., Muzanye G., Engle M., Mosher A., et al. Moxifloxacin versus ethambutol in the first two months of treatment for pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 174 3 (2006) 331-338
29. Korenromp E., Scano F., Williams B., Dye C., and Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clinical Infectious Diseases 37 (2003) 101-112
30. Menzies D., Benedetti A., Paydar A., Martin I., Royce S., Pai M., et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 6 9 (2009) e1000146
31. Mitchison D., and Coates A. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Current Pharmaceutical Design 10 26 (2004) 3285-3295
32. McCune R., Feldman F., Lambert H., and McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. Journal of Experimental Medicine 123 (1966) 445-468
33. McCune R., Feldman F., and McDermott W. Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. Journal of Experimental Medicine 123 (1965) 469-486
34. Garton N.J., Waddell S.J., Sherratt A.L., Lee S., Smith R.J., Senner C., et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 5 4 (2008 Apr 1) e75
35. Mukamolova G.V., Turapov O., Malkin J., Woltmann G., and Barer M.R. Resuscitation promoting factors reveal an occult population of tubercle bacilli in sputum. American Journal of Respiratory and Critical Care Medicine 181 2 (2010) 174-180